APR markets four established product ranges, spanning pain relief, nausea and vomiting management, anorectal care and medical nutrition for inherited metabolic disorders. Alongside these, we are advancing two development-stage programs for rare diseases. APR does not offer contract or pharmaceutical services.
Fast-acting, non-steroidal pain relief in tablet and sachet formats, distributed under several established brand names across multiple markets.
Muscadvance® · Diclo‑ADGC® · Diclo‑ratiopharm® · Itamifast® · Inflamac® · Dr. Reddy's Diclo® · Potafast® · DialRapid®
Film-coated tablets (25 mg and 50 mg) and oral powder sachets, designed for rapid relief of acute pain.
Orodispersible oral films for the management of nausea and vomiting, offering an alternative for patients who have difficulty swallowing tablets.
Ondissolve® · Setofilm®
Orodispersible films available in 4 mg and 8 mg strengths.
A dedicated cleansing foam for anorectal hygiene, complementing anorectal care routines.
Proctoderm®
Cleansing foam.
Medical foods formulated to support the dietary management of inherited metabolic disorders, available as sachets and bars.
PKU GOLIKE® (for phenylketonuria) · TYR GOLIKE® (for tyrosinemia)
Protein-equivalent sachets and flavoured bars, formulated for use across paediatric and adult patients under medical supervision.
APR is advancing two development-stage programs targeting rare diseases. Both are available for out-licensing in multiple markets.
A novel sapropterin suspension formulation being developed for the potential treatment of phenylketonuria (PKU), intended to complement APR's existing Golike medical nutrition franchise.
A development-stage program for epidermolysis bullosa (EB), a rare and severe genetic skin disease, being pursued under orphan-drug and rare paediatric disease designation frameworks.
Our regulatory affairs and pharmacovigilance teams are available for healthcare professionals and partners.
Contact Us